VYNE THERAPEUTICS INC.

(VYNE)
  Report
Delayed Nasdaq  -  03:59 2022-08-05 pm EDT
0.4151 USD   +0.75%
07/27VYNE THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
07/19VYNE Therapeutics to Present at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference
AQ
06/17VYNE Therapeutics Completes Enrollment in Trial of Atopic Dermatitis Treatment
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

VYNE Therapeutics Inc. Completes Enrollment in Phase 2A Trial of FMX 114 for the Treatment of Mild-To-Moderate Atopic Dermatitis

06/17/2022 | 08:00am EDT

VYNE Therapeutics Inc. announced the completion of enrollment in the Phase 2a study of FMX114 for the treatment of mild-to-moderate atopic dermatitis ("AD"). FMX114 is VYNE's proprietary investigational combination gel formulation of tofacitinib and fingolimod, which has been designed to address both the source and cause of inflammation in AD. In April 2022, VYNE reported positive efficacy data from the Phase 1b segment of the trial, demonstrating that treatment with FMX114 resulted in a statistically significant reduction in both absolute and percent change in mean Atopic Dermatitis Severity Index ("ADSI") score compared to vehicle. FMX114 treatment also substantially reduced pruritus (itch) as measured on the worst pruritus Numerical Rating Scale ("NRS"). The Phase 2a segment of the FMX 114 study is designed to evaluate four weeks of FMX114 treatment in patients with AD compared to vehicle control. Due to the impact of COVID-19 on enrollment and other operations related to the original trial sites in Australia, the Company activated additional clinical trial sites in the United States to support patient enrollment and expedite completion of the study. With enrollment now completed, the Company expects to report top-line efficacy results in approximately 6 to 8 weeks. After completion of this phase, these subjects may continue into a two-week open-label treatment phase and will be able to apply the active drug to both lesions. The study is being conducted at sites in Australia and in the United States.


© S&P Capital IQ 2022
All news about VYNE THERAPEUTICS INC.
07/27VYNE THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form..
AQ
07/19VYNE Therapeutics to Present at the B&T Cell-Mediated Autoimmune Disease Drug Developme..
AQ
06/17VYNE Therapeutics Completes Enrollment in Trial of Atopic Dermatitis Treatment
MT
06/17VYNE THERAPEUTICS : Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of ..
PU
06/17VYNE THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Other Events, Financi..
AQ
06/17VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of..
AQ
06/17VYNE Therapeutics Inc. Completes Enrollment in Phase 2A Trial of FMX 114 for the Treatm..
CI
05/18VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference
AQ
05/17VYNE THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form..
AQ
05/17TRANSCRIPT : VYNE Therapeutics Inc. - Special Call
CI
More news
Analyst Recommendations on VYNE THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2022 0,43 M - -
Net income 2022 -37,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,71x
Yield 2022 -
Capitalization 24,1 M 24,1 M -
Capi. / Sales 2022 55,5x
Capi. / Sales 2023 96,3x
Nbr of Employees 28
Free-Float 98,6%
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VYNE THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 0,42 $
Average target price 6,00 $
Spread / Average Target 1 345%
EPS Revisions
Managers and Directors
David Domzalski President, Chief Executive Officer & Director
Tyler Zeronda Chief Financial Officer & Treasurer
Iain A. Stuart Chief Scientific Officer
Sharon Barbari Independent Director
Steven L. Basta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VYNE THERAPEUTICS INC.-59.30%24
JOHNSON & JOHNSON0.02%449 879
ELI LILLY AND COMPANY9.09%286 307
PFIZER, INC.-15.56%276 449
ROCHE HOLDING AG-16.46%271 358
ABBVIE INC.2.60%244 068